Skip to content

Fulcrum Therapeutics, Inc.

FULC· NasdaqCore metricsCIK 1680581

Pharmaceutical preparations552 peers

Close
Oct 27, 2026 · +0.54%
Market cap
$282.61M
76.38M shares
Filings
527
$0.00
FY 2025−100.0% FY25 yoy
-$10.94M
Q3 2026N/M FY25 yoy
-$13.86M
Q3 2026N/M FY25 yoy
-$48.29M
Q3 2026derivedN/M FY25 yoy
-$0.14
Q3 2026N/M FY25 yoy
$116.41M
Q3 2026+239.3% FY25 yoy
$282.61M
—
—
0.9×
-21.36%
—

FY2025 figures · derived

Price

$3.7061.62%$5.94past year
Oct 27, 2026 · Official close
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00FY 2025
$80.00M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$0reported
FY 20242024-12-31$80,000,000reported
FY 20232023-12-31$2,805,000reported
FY 20222022-12-31$6,342,000reported
FY 20212021-12-31$19,163,000reported
FY 20202020-12-31$8,823,000reported

Pharmaceutical preparations

Fulcrum Therapeutics, Inc. is the 225th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR